Medicinal chemistry – Page 68
-
Business
Bayer and Evotec team up on endometriosis
German collaboration aims to develop three drug candidates in five years
-
OpinionColour and controversy
Bob Hefford considers the spotted past and uncertain future of the chemicals that built the hair dye industry
-
NewsChinese drug makers accused of using ‘gutter oil’
Oil reclaimed from drains may have been used to make an antibiotic intermediate
-
FeatureFood with a function
Compounds normally thought of as medicines are being added to food. Elinor Hughes looks at the scientific and regulatory challenges facing these nutraceuticals.
-
Business
Alzheimer's drug flops in Phase III
Solanezumab from Eli Lilly missed the cognitive and functional primary endpoints of the trials
-
OpinionProtecting patients at all costs
Suffering stagnant output, and beset by patent expiries and spiralling costs, drug discovery is in poor health. Simon Campbell prescribes a remedy
-
OpinionMonopoly money
Dean Baker says it’s time to start talking seriously about the way in which pharma is funded
-
FeatureFast, flexible and flourishing
Paul Workman’s experiences in big pharma, academia and biotech gave him the tools to develop new drugs and spin out successful companies. Sarah Houlton profiles the 2012 Chemistry World entrepreneur of the year
-
FeatureThe latent threat of tuberculosis
Although TB was close to being eradicated in the developed world, it is a major problem in developing countries. With drug-resistant strains on the increase, Clare Sansom outlines the latest in the fight against this killer disease
-
PodcastChloral hydrate
Dubbed the 'Mickey Finn', this week's compound has uses in medicine and manipulation
-
-
Business
First HIV drug approved as prevention
Truvada tablets can reduce the risk of infection for an HIV-negative person
-
FeatureDrawing on drugs to kick the habit
While pharma companies stand accused of giving up on drugs to help people stop smoking, tobacco firms are looking at controversial nicotine replacement products. Anthony King surveys an area that is problematic on all sides.
-
Business
GSK drug shines in HIV trial
HIV–Aids drug candidate dolutegravir outperformed Atripla tablets in Phase III
-
-
OpinionSilicone safety: the status quo
Public alarm over the use of silicone is unwarranted, says Alan Lansdown
-
Business
Good signs for Merck & Co insomnia pill
Suvorexant switches off wakefulness to help patients drop off quicker and stay asleep longer
-
Business
More testing needed for ridaforolimus
Marketing approval for anti-cancer drug ridaforolimus has been held up in the US
-
News€224 million EU antibiotics initiative launched
The project will bring together the pharmaceutical industry and academia, but some institutes have reservations